Superworth60 Degrees Pharmaceuticals EPS SXTP
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.90
- Fiscal year 2024
- −$98.00
60 Degrees Pharmaceuticals' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.90.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$98.00 | n/a |
| FY2023 | −$511.80 | n/a |
| FY2022 | −$624.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.90 | n/a | n/a | |
| Q1 FY26 | −$1.28 | n/a | n/a | |
| Q3 FY25 | −$2.64 | n/a | −$23.06 | |
| Q2 FY25 | −$5.01 | n/a | −$32.10 | |
| Q1 FY25 | −$6.25 | −185% | −$111.57 | |
| Q4 FY24 | −$9.16 | n/a | −$98.00 | |
| Q3 FY24 | −$11.68 | −106% | −$175.24 | |
| Q2 FY24 | −$84.48 | n/a | $19.04 | |
| Q1 FY24 | $7.32 | n/a | −$233.28 | |
| Q4 FY23 | −$86.40 | n/a | −$511.80 | |
| Q3 FY23 | $182.60 | n/a | −$591.00 | |
| Q2 FY23 | −$336.80 | n/a | −$920.00 |
Against its peers
Companies in Healthcare nearest 60 Degrees Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SXTP60 Degrees Pharmaceuticals | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on 60 Degrees Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.